Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has notified the market that its shares will remain suspended as its interim results are delayed, pending completion of audit.
It comes after preceding full-year financials were delayed in December 2022 and its shares were suspended in January.
“The company is actively working to finalise the audit and publication of its 2022 annual report and accounts and its interim results. Allergy Therapeutics remains in active discussions regarding its funding situation and will update the market in due course,” it said in a stock market statement.